-
Je něco špatně v tomto záznamu ?
Cardiotoxicity of β-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy
B. Ostadal, A. Parizek, I. Ostadalova, F. Kolar,
Jazyk angličtina Země Kanada
Typ dokumentu časopisecké články, přehledy
PubMed
29633627
DOI
10.1139/cjpp-2017-0774
Knihovny.cz E-zdroje
- MeSH
- adenylátcyklasy metabolismus MeSH
- agonisté adrenergních beta-receptorů škodlivé účinky MeSH
- beta-adrenergní receptory metabolismus MeSH
- kardiotoxicita etiologie MeSH
- katecholaminy škodlivé účinky MeSH
- lidé MeSH
- signální transdukce účinky léků MeSH
- srdce účinky léků embryologie MeSH
- těhotenství MeSH
- tokolytika škodlivé účinky MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Catecholamines are involved in the regulation of a wide variety of vital functions. The β-adrenergic receptor (β-AR) - adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of β-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the β-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of β-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the β-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of β-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to β-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in β-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of β-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000817
- 003
- CZ-PrNML
- 005
- 20190115100629.0
- 007
- ta
- 008
- 190107s2018 xxc f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1139/cjpp-2017-0774 $2 doi
- 035 __
- $a (PubMed)29633627
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxc
- 100 1_
- $a Ostadal, B $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
- 245 10
- $a Cardiotoxicity of β-mimetic catecholamines during ontogenetic development - possible risks of antenatal therapy / $c B. Ostadal, A. Parizek, I. Ostadalova, F. Kolar,
- 520 9_
- $a Catecholamines are involved in the regulation of a wide variety of vital functions. The β-adrenergic receptor (β-AR) - adenylyl cyclase system has been identified early in embryogenesis before the heart has received adrenergic innervation. The structure of β-receptors in the immature myocardium is similar to that in adults; there are, however, significant quantitative developmental changes in the inotropic and chronotropic responsiveness. Information on the toxic effect of the β-AR agonists in the immature heart is surprisingly scarce, even though these agents are used in clinical practice both during pregnancy and in early postnatal development. Large doses of β-AR agonists induce malformations of the cardiovascular system; the type of change depends upon the time at which the β-AR agonist was administered during embryogenesis. During postnatal ontogeny, the cardiotoxicity of β-AR agonists increased from birth to adulthood. It seems likely that despite interspecies differences, developmental changes in the cardiac sensitivity to β-AR agonists may exist in all mammals, depending on the degree of maturation of the system involved in β-adrenergic signaling. All the existing data draw attention to the possible harmful consequences of the clinical use of β-AR agonists during early phases of cardiac development. Late effects of the early disturbances of the cardiac muscle cannot be excluded.
- 650 _2
- $a adenylátcyklasy $x metabolismus $7 D000262
- 650 _2
- $a agonisté adrenergních beta-receptorů $x škodlivé účinky $7 D000318
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kardiotoxicita $x etiologie $7 D066126
- 650 _2
- $a katecholaminy $x škodlivé účinky $7 D002395
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a srdce $x účinky léků $x embryologie $7 D006321
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a beta-adrenergní receptory $x metabolismus $7 D011943
- 650 _2
- $a signální transdukce $x účinky léků $7 D015398
- 650 _2
- $a tokolytika $x škodlivé účinky $7 D015149
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Parizek, A $u b Department of Obstetrics and Gynecology, 1st Faculty of Medicine, Charles University and General Faculty Hospital, Prague, Czech Republic.
- 700 1_
- $a Ostadalova, I $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
- 700 1_
- $a Kolar, F $u a Institute of Physiology, Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
- 773 0_
- $w MED00001020 $t Canadian journal of physiology and pharmacology $x 1205-7541 $g Roč. 96, č. 7 (2018), s. 639-646
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29633627 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190115100840 $b ABA008
- 999 __
- $a ok $b bmc $g 1364813 $s 1038940
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 96 $c 7 $d 639-646 $i 1205-7541 $m Canadian journal of physiology and pharmacology $n Can J Physiol Pharmacol $x MED00001020
- LZP __
- $a Pubmed-20190107